回复：F. 约翰内斯·P. 范·瓦伦贝格、安德鲁·M. 希亚尔、艾伦·华莱士等。基于mRNA的尿液检测用于膀胱癌患者监测的前瞻性验证。《欧洲泌尿外科杂志》2019年；75卷：853 - 860页。 - Suppr | 超能文献

Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol 2019;75:853-60.

作者信息

Pichler Renate, Heidegger Isabel

机构信息

Department of Urology, Medical University Innsbruck, Innsbruck, Austria.

Department of Urology, Medical University Innsbruck, Innsbruck, Austria.

出版信息

Eur Urol. 2019 Jun;75(6):e175-e176. doi: 10.1016/j.eururo.2019.02.016. Epub 2019 Feb 23.

DOI:10.1016/j.eururo.2019.02.016

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol 2019;75:853-60.

Eur Urol. 2019 Jun;75(6):e175-e176. doi: 10.1016/j.eururo.2019.02.016. Epub 2019 Feb 23.

2

Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol. 2019; 75,5: 853-860.

Eur Urol. 2019 Oct;76(4):e111-e112. doi: 10.1016/j.eururo.2019.05.003. Epub 2019 May 10.

3

Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes Bründl, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol 2021;4:182-91: Image Analysis, Nuclear Abnormality Index, and Pattern Recognition Analysis.

Eur Urol Oncol. 2021 Aug;4(4):671-673. doi: 10.1016/j.euo.2021.06.002. Epub 2021 Jun 16.

4

Re: Bas W.G. van Rhijn, Theo H. van der Kwast, Sultan S. Alkhateeb, et al. A New and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61:378-84.

Eur Urol. 2012 Jun;61(6):e53-4; author reply e55-6. doi: 10.1016/j.eururo.2012.03.016. Epub 2012 Mar 21.

5

Re: Bas W.G. van Rhijn, Theo H. van der Kwast, Sultan S. Alkhateeb, et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61:378-84.

Eur Urol. 2012 Apr;61(4):e31-2; author reply e33-4. doi: 10.1016/j.eururo.2012.01.005. Epub 2012 Jan 11.

6

Re: Edwin E. Morales, Sonja Grill, Robert S. Svatek, et al. Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. Eur Urol 2016;69:407-10.

Eur Urol. 2016 Mar;69(3):e57-8. doi: 10.1016/j.eururo.2015.11.021. Epub 2015 Dec 9.

7

Reply from authors re: Brant A. Inman, Michael R. Abern. Interpreting a study on bladder cancer screening. Eur Urol 2013;64:48-50: the goal of cancer screening: early evaluation of screening for bladder cancer.

Eur Urol. 2013 Jul;64(1):50-1. doi: 10.1016/j.eururo.2013.04.021. Epub 2013 Apr 19.

8

A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.

Can J Urol. 2004 Dec;11(6):2438-44.

9

Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.

Eur Urol. 2015 Aug;68(2):e33-4. doi: 10.1016/j.eururo.2015.02.043. Epub 2015 Mar 13.

10

Re: Anobel Y. Odisho, Anna B. Berry, Ardalan E. Ahmad, Matthew R. Cooperberg, Peter R. Carroll, Badrinath R. Konety. Reflex immunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology. Eur urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.04.019.

Eur Urol. 2012 Nov;62(5):e87; author reply e88. doi: 10.1016/j.eururo.2012.07.050. Epub 2012 Aug 9.